Method of Detecting and Treating Tuberous Sclerosis Complex Associated Disorders
AssigneeCelldex Therapeutics, Inc.
InventorsLuca Rastelli, Bonnie Gould-Rothberg, Ryan Murphey
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of detecting and treating tuberous sclerosis complex associated disorders. Also disclosed are methods of identifying agents for treating tuberous sclerosis complex associated disorders.
Claims20
A method of diagnosing or determining the susceptibility to a tuberous sclerosis complex associated disorder in a subject, the method comprising:
- (a) providing from the subject a test cell population comprising cells capable of expressing one or more nucleic acid sequences selected from the group consisting of TSC 1-8, 10-12, 15-141 and 142;
- (b) measuring expression of one or more of the nucleic acid sequences in the test cell population;
- and (c) comparing the expression of the nucleic acid sequences in the test cell population to the expression of the nucleic acid sequences in a reference profile comprising at least one cell from a subject not suffering from a tuberous sclerosis complex associated disorder;
- and (d) identifying a difference in expression levels of the nucleic acid sequences, if present, in the test cell population and reference profile, thereby diagnosing or determining the susceptibility to a tuberous sclerosis complex associated disorder in the subject.
An isolated nucleic acid comprising a nucleic acid sequence selected from the group consisting of a TSC 1-8, 10-12, 15-25 gene, and its complement.
A method of treating a disease or disorder characterized by aberrant expression or activity of NMB, said method comprising administering the isolated antibody that immunospecifically binds to an NMB polypeptide.
Dependencies are inferred from the claim text.